New Endocrine Therapies for Breast Cancer

European Journal of Cancer

Volumn 32, Issue 4, 1996, Pages 576-588

  Howell, A ^a   Downey, S ^c   Anderson, E ^b  

^a CRC Department of Medical Oncology   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; DROLOXIFENE; EXEMESTANE; FADROZOLE; FORMESTANE; FULVESTRANT; IDOXIFENE; LETROZOLE; MIFEPRISTONE; MIPROXIFENE PHOSPHATE; ONAPRISTONE; PLOMESTANE; PYRIDOGLUTETHIMIDE; RALOXIFENE; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; VOROZOLE;

BREAST CANCER; FEMALE; HORMONAL THERAPY; HUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MICE; RATS;

EID: 0030006471     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00032-9     Document Type: Article

References (106)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet 1896, ii, 104-107.
2. Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol 1902, 28, 325-353.
3. Howell A, DeFriend D, Anderson E. Mechanisms of response and resistance to endocrine therapy for breast cancer and the development of new treatments. Rev Endocrin-Rel Cancer 1993, 43, 5-21.
4. Haddow A, Watkinson JM, Patterson E. Influence of synthetic oestrogens upon advanced malignant disease. Br Med J 1944, 2, 393-398.
5. Walpole AL, Patterson E. Synthetic oestrogens in mammary cancer. Lancet 1949, ii, 783-786.
6. Cole MP, Jones CTA, Todd IDH. A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of ICI 146474. Br J Cancer 1971, 25, 270-275.
7. Powles T, Jones AC, Ashley SE. The Royal Marsden Hospital Pilot Tamoxifen Chemoprevention trial. Breast Cancer Res Treat 1994, 31, 73-82.
8. Webster NJG, Green S, Jin JR, Chambon P. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 1988, 54, 199-207.
9. Tora L, White J, Brou C, et al. The human estrogen receptor has two independent nonacid transcriptional activation functions. Cell 1989, 59, 477-487.
10. Fawell SE, White R, Hoare S, Syndenham M, Page M, Parker MG. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 1990, 87, 6883-6887.
11. De Friend DJ, Howell A, Nicholson RI, et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994, 54, 408-414.
12. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992, 89, 4037-4041.
13. Kangas L, Nieminen A-L, Blanco G, et al. A new triphenylethylene compound, Fc-1157a. II. Antimmor effects. Cancer Chemother Pharmacol 1986, 17, 109-113.
14. Loser R, Seibel K, Roos W, Eppenberger U. In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen. Eur J Cancer Clin Oncol 1985, 21, 985-990.
15. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiopene derived antiestrogen. Life Sci 1983, 32, 1031-1036.
16. Toko T, Sugimoto Y, Matsuo E, et al. TAT-59, a new triphenylethylene derivative with antitumour activity against hormone-dependent tumors. Eur J Cancer 1990, 26, 397-404.
17. Chander SK, McCague R, Luqmani Y, et al. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the anti-estrogen tamoxifen for the treatment of breast cancer. Cancer Res 1991, 51, 5851-5858.
18. Wantanabe T, Wu JZ, Morikawa K, et al. In vitro sensitivity test of breast cancer cells to hormonal agents in a radionucleotide-incorporation assay. Jpn J Cancer Res 1990, 81, 536-543.
19. Tominaga T, Yoshida Y, Matsumoto A, Hayashi K, Kosaki G. Effects of tamoxifen and the derivative (TAT) on cell cycle of MCF-7 in vitro. Anticancer Res 1993, 13, 661-666.
20. Roos W, Oeze L, Loser R, Eppenberger U. Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7. J Natl Cancer Inst 1983, 71, 55-59.
21. Kawamura I, Mizota T, Mukumoto S, et al. Antioestrogenic and antitumour effects of droloxifene in experimental breast carcinoma. Arzneimittelforschung 1989, 39, 889-893.
22. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987, 47, 4020-4024.
23. Jones CD, Jevnikar MG, Pike AJ, et al. Antiestrogens. 2. Structure-activity studies in a series of 3-aroxyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [2-(piperidinyl) ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem 1984, 27, 1057-1066.
24. Toko T, Matsuo K-I, Shibata I, et al. Interaction of DP-TAT-59, an active metabolite of new triphenylethylene derivative (TAT-59) with estrogen receptors. J Steroid Biochem Mol Biol 1992, 43, 507-514.
25. Dowsett M, Johnston SRD, Westley BR, et al. Idoxifene retains effectiveness in tamoxifen resistant MCF-7 cells in vitro and in vivo. 5th International Congress, 1995. Québec, Canada.
26. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991, 51, 3867-3873.
27. Kangas L. Review of the pharmacological properties of toremifene. J Steroid Biochem 1990, 36, 191-195.
28. Eppenberger U, Wosikowski K, Kung W. Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol 1991, 14 (Suppl. 2), 5-14.
29. Hardcastle IR, Rowlands MG, Houghton J, Parr IB, Potter GA, Jarman M. Rationally designed analogues of tamoxifen with improved calmodulin antagonism. J Med Chem 1995, 38, 241-248.
30. Stenbygaard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SA, Dombernowsky P. Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial. Breast Cancer Res Treat 1993, 25, 57-63.
31. Hayes DE, Van Zyl JA, Hacking A, et al. A randomised comparison of tamoxifen (TAM) and two separate doses of toremifene (TOR) in postmenopausal patients with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1995, 14, 93 (Abst. No. 71).
32. Valavaara R. Phase II trials with toremifene in advanced breast cancer: a review. Breast Cancer Res Treat 1990, 16 (Suppl. 16), 31-35.
33. Rauschning W, Pritchard KI. Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res Treat 1994, 31, 83-94.
34. Ebbs SR, Roberts J, Baum M. Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication. J Steroid Biochem 1990, 36, 239.
35. Jonsson PE, Malmberg M, Bergljung L, et al. Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifene treatment. Anticancer Res 1991, 11, 873-875.
36. Pyrhonen S, Valavaara R, Vuorinen J, Hajba A. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res Treat 1994, 29, 223-228.
37. Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR. Multicenter phase II efficacy trial of toremifene in tamoxifenrefractory patients with advanced breast cancer. J Clin Oncol 1993, 11, 345-350.
38. Haarstad H, Gundersen S, Wist E, Raabe N, Mella O, Kvinnsland S. Droloxifene - a new anti-estrogen. A phase II study in advanced breast cancer. Acta Oncol 1992, 31, 425-428.
39. Buzdar AU, Marcus C, Holmes F, et al. Phase 2 evaluation of LY156758 in metastatic breast cancer. Oncology 1988, 45, 344-345.
40. Coombes RC, Haynes BP, Dowsett M, et al. Idoxifene: report of a phase I study in patients with metastatic breast cancer. Cancer Res 1995, 55, 1070-1074.
41. Howell A, Mackintosh J, Jones M, et al. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988, 24, 1567-1572.
42. Litherland S, Jackson I. Anti-oestrogens in the management of hormone-dependent cancer: a review. Cancer Treat Rev 1988, 15, 183-194.
43. Draper MW, Flowers DE, Huster WJ, Neild JA. Effects of raloxifene (LY139481 HCI) on biochemical markers of bone and lipid metabolism in healthy postmenopausal women. In Christiansen C, Riis B, eds. Proceedings 1993. Fourth International Symposium on Ostoporosis and Consensus Development Conference. Aalborg, Denmark: Handelstrykkeriet. Aalborg, ApS, 1993, 119-121.
44. Wiebe VJ, Benz CC, Shemano I, Cadman TB, DeGregorio MW. Pharmacokinetics of toremifene and its metabolities in patients with advanced breast cancer. Cancer Chemother Pharmacol 1990, 25, 247-251.
45. Tanaka Y, Sekiguchi M, Sawamoto T, et al. Pharmacokinetics of droloxifene in mice, rats, monkeys, premenopausal and postmenopausal patients. Eur J Drug Metab Pharmacokinet 1994, 19, 47-58.
46. Grill HJ, Pollow K. Pharmacokinetics of droloxifene and its metabolites in breast cancer patients. Am J Clin Oncol 1991, 14 (Suppl. 2), 21-29.
47. Howell A, Dodwell D, Anderson H, Redford J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 1992, 3, 611-617.
48. Wakeling AE, Bowler J. Steroidal pure anti-oestrogens. J Endocrinol 1987, 112, R7-R10.
49. Nédelec L, Bouton MM, Nique F, van de Velde P. Synthesis and estrogenic antiestrogenic activities of a series of 7 alpha-aryl-estradiols and comparison with 11β-aryl estradiols. Proceedings 8th Int Congress on Hormonal Steroids, The Hague, The Netherlands, 1990, Abst. 302.
50. Levesque C, Mérand Y, Dufour JM, Labrie C, Labrie F. Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem 1991, 34, 1624-1630.
51. Claussner A, Nédelec L, Nique F, Philibert D, Teutsch G, Van De Velde P. 11 beta-amidalkyl estradiols, a new series of pure antiestrogens. J Steroid Biochem Mol Biol 1992, 41, 609-614.
52. Auger S, Mérand Y, Pelletier JD, Poirier D, Labrie F. Synthesis and biological activities of thioether derivatives related to the anti-oestrogens tamoxifen and ICI 164384. J Steroid Biochem Mol Biol 1995, 52, 547-565.
53. Wakeling AE, Bowler J. Novel anti-oestrogens without partial agonist activity. J Steroid Biochem 1988, 31, 645-653.
54. Osborne CK, Coronadoheinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995, 87, 748-750.
55. Gallagher A, Chambers TJ, Tobias JH. The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology 1993, 133, 2787-2791.
56. Wakeling AE. Are breast tumours resistant to tamoxifen also resistant to pure anti-oestrogens. J Steroid Biochem Mol Biol 1993, 47, 107-114.
57. 1. Cancer Res 1994, 54, 1587-1595.
58. Coopman P, Garcia M, Brunner N, Derocqu D, Clarke R, Rochefort H. Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast cancer cells. Int J Cancer 1994, 56, 295-300.
59. Tominaga T. Early phase II clinical study of TAT-59 (new antiestrogen) in patients with advanced breast cancer. 19th International Congress of Chemotherapy, 1995. Montréal, Québec, Canada.
60. Howell A, DeFriend D, Anderson E. Clues to the mechanisms of endocrine resistance from clinical studies in advanced breast cancer. Endocrin-Rel Cancer 1995, 2, 131-139.
61. Howell A, DeFriend D, Robertson J, Blarney R, Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995, i, 29-30.
62. DeFriend DJ, Anderson E, Bell J, et al. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer 1994, 70, 204-211.
63. Gottardis MM, Jiang S-Y, Jeng M-H, Jordan VC. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 1989, 49, 4090-4093.
64. Thomas EJ, Walton PL, Thomas NM, Dowsett M. The effects of ICI 182780, a pure anti-oestrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in premenopausal women. Hum Reprod 1994, 9, 1991-1996.
65. Wakeling AE. The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 1993, 25, 1-9.
66. Nicholson RI, Francis AB, McClelland RA, Manning DI, Gee JMW. Pure anti-oestrogens (ICI 164384 and ICI 182780) and breast cancer: is the attainment of complete oestrogen withdrawal worthwile? Endocrin-Rel Cancer 1994, 1, 5-17.
67. Nicholson RI, Gee JMW, Eaton CL, et al. Pure anti-oestrogens in breast cancer: experimental and clinical observations. In Monta M, Serio M, eds. Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Amsterdam, Elsevier, 1994, 347-360.
68. Griffiths CT, Hall TC, Saba Z, Barlow JJ, Nevinny HB. Preliminary trial of aminoglutethimide in breast cancer. Cancer 1973, 32, 31-37.
69. Di Salle E, Ornati G, Paridaens R, et al. Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304). In Motta M, Serio M, eds. Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Amsterdam, Elsevier, 1994, 303-309.
70. Dowsett M, MacNeill F, Mehta A, et al. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2, 6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. Br J Cancer 1991, 64, 887-894.
71. Santen RJ, Demers LM, Adlercreutz H, et al. Inhibition of aromatase with CGS 16949A in postmenopausal women. J Clin Endocrinol Metab 1989, 68, 99-106.
72. Johnston SRD, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 1994, 54, 5875-5880.
73. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 1993, 53, 266-270.
74. Lipton A, Demers LM, Harvey HA, et al. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 1995, 75, 2132-2138.
75. Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994, 30, 103-111.
76. Murray R, Pitt P. Aromatase inhibition with 4-OH androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 1995, 35, 249-253.
77. Lonning PE, Dowsett M, Jones A, et al. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyadrostenedione treatment. Breast Cancer Res Treat 1992, 23, 57-62.
78. Samojlik E, Santen RJ, Worgul TJ. Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy. Clin Endocrinol 1984, 20, 43-51.
79. Bundred NJ, Eremin O, Stewart HJ, et al. Beneficial response to pituitary ablation following aminoglutethimide. Br J Surg 1986, 73, 388-389.
80. Dowsett M, Stein RC, Coombes RC. Aromatase inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem 1992, 43, 155-159.
81. Schultz J, Fox K, Conner G, Glick J, Capizzi RL. A phase II study of rogletimide (ROG) in females with advanced/metastatic breast cancer (A/M BrCa). Proc Am Soc Clin Oncol 1995, 14, 93 (Abst. No. 73).
82. Thurlimann B, Beretta K, Bacchi M, et al. First line fadrozole HCl (CGS 16949A) versus tamoxifen (TAM) in advanced breast cancer: prospective randomised study SAKK 20/88. Proc Am Soc Clin Oncol 1995, 14, 98 (Abst. No. 90).
83. Jonat W, Howell A, Blomqvist CP, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer (ABC). Eur J Cancer 1996, 32A, 404-412.
84. Harnett AN, Canney P, Coombes RC, et al. A randomised phase II trial of rogletimide in heavily pretreated breast cancer patients. Proc Am Soc Clin Oncol 1995, 14, 176 (Abst. No. 388).
85. Falkson G, Raats JI, Falkson HC. Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer. J Steroid Biochem Mol Biol 1992, 43, 161-165.
86. Miller A, Lipton A, Henderson I, et al. Fadrozole hydrochloride in postmenopasual patients with metastatic breast cancer. Clin Cancer Res, submitted.
87. Buzdar AU, Smith R, Vogal C, et al. Fadrozole HCl (CGS-16949A) versus megestrol acetate in post menopausal patients with metastatic breast carcinoma: results of two randomised double-blind controlled multi-institutional trials. Cancer, submitted.
88. Thürlimann B, Paridaens R, Roche M, et al. Exemestane in postmenopausal pretreated advanced breast cancer: a multicenter phase II study in patients with aminoglutethimide (AG) failure. Proc ESMO 1994, 5 (Suppl. 8), 144 (Abst.).
89. Buzdar AU, Plourde PV, Jones SE, Vogel CL, Wolters JM, Esienberg PD. A randomised phase III study of the new selective aromatase inhibitor arimidex (A) (ZD 1033) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer. Proc Nottingham Int Breast Meeting 1995, Abst. 169.
90. Baulieu EE. The anti-steroid RU 486. Its cellular and molecular mode of action. Trends Endocrinol Metab 1991, 2, 233-239.
91. McDonnell DP, Goldman ME. RU486 exerts antiestrogenic activities through a novel progesterone receptor. A form-mediated mechanism. J Biochem Chem 1994, 269, 11,945-11,949.
92. Kraus WL, Weis KE, Katzenellenbogen BS. Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol Cell Biol 1995, 15, 1847-1857.
93. Jeng M-H, Langan-Fahey SM, Jordan VC. Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells. Endocrinology 1993, 132, 2622-2630.
94. Kloosterboer HJ, Deckers GH, Schoonen WGEJ. Pharmacology of two new very selective antiprogestagens: Org 31710 and Org 31806. Hum Reprod 1994, 9 (Suppl. 1), 47-52.
95. 1. Cancer Res 1994, 54, 3868-3877.
96. Bardon S, Vignon F, Chalbos D, Rochefort M. RU38486, a progestin and glucorticoid antagonist, inhibits the growth of breast cancer via the progesterone receptor. J Clin Endocrinol Metab 1985, 60, 692-697.
97. Classen S, Possinger K, Pelka-Fleischer R, Wilmanns W. Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells. J Steroid Biochem Mol Biol 1993, 45, 315-319.
98. Schneider MR, Michna H, Habenicht UF, Nishino Y, Grill HJ, Pollow K. The tumour-inhibiting potential of the progesterone antagonist onapristone in the human mammary carcinoma T61 in nude mice. J Cancer Res Clin Oncol 1992, 118, 187-189.
99. Bakker GH, Setyono Han B, Portengen H, De-Jong FH, Foekens JA, Klijn JG. Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 1990, 37, 789-794.
100. Schneider MR, Michna H, Nishino Y, Neef G, el-Etreby MF. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors. Anticancer Res 1990, 10, 683-687.
101. Michna H, Nishino Y, Neef G, McGuire WL, Schneider MR. Progesterone antagonists: tumor-inhibiting potential and mechanism of action. J Steroid Biochem Mol Biol 1992, 41, 339-348.
102. Horwitz KB. The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocrin Rev 1992, 13, 146-163.
103. Romieu G, Maudclonde T, Ulmann A, et al. The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 1987, 74, 455-460.
104. Klijn JGM, de Jong FH, Bakker GH, Lambets SWJ, Rodenburg CJ, Alexieva-Figusch J. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 1989, 49, 2851-2856.
105. Eisenhauer EA, Pritchard KI, Perrault D, et al. Phase II study of mifepristone (RU486) in previously untreated patients (PTS) with metastatic breast cancer (BC): a trial of the NCI Canada Clinical Trials Group (NCIC CTG). ASCO Proc 1995 (Abst. 154).
106. Jonat W. Antiprogestins. Breast, in press.